Microbiota restoration therapy (MRT), compositions and methods of manufacture
Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
1. A method of treating a gastrointestinal disorder, the method comprising:
administering a first pre-treatment antibiotic to a patient with a gastrointestinal disorder;
wherein the gastrointestinal disorder includes a Clostridium difficile infection;
administering a second pre-treatment antibiotic to the patient with the gastrointestinal disorder;
wherein the first pre-treatment antibiotic and the second pre-treatment antibiotic are different;
administering a first dose of the microbiota restoration therapy composition to the patient;
wherein administering a first dose of the microbiota restoration therapy composition to the patient includes administering the first dose of the microbiota restoration therapy composition the patient via an enema; and
wherein the microbiota restoration therapy composition comprises an effective amount of fecal microbiota from a fresh human fecal sample suspended in a solution that includes polyethylene glycol at a concentration of 30-90 g/L in saline.
2. The method of claim 1 , wherein the first pre-treatment antibiotic, the second pre-treatment antibiotic, or both includes vancomycin, fidaxomicin, rifaximimin, linezolid, daptomycin, quinupristin-dalfopristin, tigecycline, ceftaroline, ceftobiprole, televancin, teicoplanin, dalbavancin, metronidazole, ortivancin, or a combination thereof.
3. The method of claim 1 , wherein the first pre-treatment antibiotic, the second pre-treatment antibiotic, or both are administered at a dose of 0.01 mg per day to 5000 mg per day.
4. The method of claim 1 , wherein the first pre-treatment antibiotic, the second pre-treatment antibiotic, or both are administered orally, by enema, or by suppository.
5. The method of claim 1 , wherein the first pre-treatment antibiotic, the second pre-treatment antibiotic, or both are administered as a single dose.
6. The method of claim 1 , wherein the first pre-treatment antibiotic, the second pre-treatment antibiotic, or both are administered as two or more doses.
7. The method of claim 1 , further comprising administering a post-treatment antibiotic to the patient after administering the microbiota restoration therapy composition to the patient.
8. The method of claim 7 , wherein the post-treatment antibiotic is the same as one of the first or second pre-treatment antibiotic.
9. The method of claim 7 , wherein the post-treatment antibiotic is different from one of the first or second pre-treatment antibiotic.
10. The method of claim 1 , further comprising administering a second dose of the microbiota restoration therapy composition to the patient.
11. The method of claim 1 , wherein administering the first pre-treatment antibiotic to the patient with the gastrointestinal disorder includes administering two or more doses of the first pre-treatment antibiotic to the patient and wherein administering the microbiota restoration therapy composition to the patient includes administering two or more doses of the microbiota restoration therapy composition to the patient.
12. The method of claim 1 , further comprising pre-cooling the microbiota restoration therapy composition and freezing the microbiota restoration therapy composition prior to administration.
13. The method of claim 12 , wherein administering the microbiota restoration therapy composition to the patient includes thawing the microbiota restoration therapy composition and administering the microbiota restoration therapy composition with an enema tube.
14. A method of treating a gastrointestinal disorder, the method comprising:
pre-treating a patient with a gastrointestinal disorder with a primary dose of a first antibiotic, the first antibiotic including vancomycin, fidaxomicin, rifaximimin, linezolid, daptomycin, quinupristin-dalfopristin, tigecycline, ceftaroline, ceftobiprole, televancin, teicoplanin, dalbavancin, metronidazole, ortivancin, or a combination thereof;
wherein the gastrointestinal disorder includes a Clostridium difficile infection;
pre-treating the patient with a secondary dose of a second antibiotic, the second antibiotic including vancomycin, fidaxomicin, rifaximimin, linezolid, daptomycin, quinupristin-dalfopristin, tigecycline, ceftaroline, ceftobiprole, televancin, teicoplanin, dalbavancin, metronidazole, ortivancin, or a combination thereof;
administering a dose of a microbiota restoration therapy composition to the patient via an enema, wherein the microbiota restoration therapy composition is manufactured by mixing a fresh stool sample with saline and polyethylene glycol, the polyethylene glycol being added at a concentration of 30-90 g/L.
15. The method of claim 14 , further comprising administering a post-treatment antibiotic to the patient after administering the microbiota restoration therapy composition to the patient.
16. The method of claim 14 , further comprising administering a second dose of the microbiota restoration therapy composition to the patient.
17. The method of claim 14 , wherein administering the microbiota restoration therapy composition to the patient includes administering the microbiota restoration therapy composition with an enema tube.
18. A method of treating a Clostridium difficile infection, the method comprising:
administering a primary dose of a fecal-derived microbiota restoration therapy composition to a patient via an enema;
wherein the fecal-derived microbiota restoration therapy composition is manufactured by mixing a fresh stool sample with saline and polyethylene glycol, the polyethylene glycol being added at a concentration of 30-90 g/L; and
administering a secondary dose of the fecal-derived microbiota restoration therapy composition to the patient.